The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended EU approval of Roche’s cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel, Switzerland-based company said.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.
Swiss group Roche Holding AG said the company’s Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.
A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.